ArticleNature biomedical engineering2021
Pathogen-specific antimicrobials engineered de novo through membrane-protein biomimicry.
Article in Nature biomedical engineering, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 32 citations in OpenAlex.
- Iron-Reversible Bactericidal Activity of Marine-DerivedMarine drugs · 2026Article
- Modular peptide nanofibres that self-assemble on bacterial membranes overcome antimicrobial resistance.Nature biomedical engineering · 2026Article
- Review
- Harnessing Piezoelectric Biomaterials for Pathogenic Eradication and Tissue Regeneration.Exploration (Beijing, China) · 2026Review
- Retro-inversion imparts antimycobacterial specificity to host defense peptides.Nature communications · 2025Article
- Lead Informed Artificial Intelligence Mining of Antitubercular Host Defense Peptides.Biomacromolecules · 2025Article
- Injectable iodine-containing peptide hydrogel for treatment of MRSA infection.Bioactive materials · 2025Article
- Specifically targeted antimicrobial peptides synergize with bacterial-entrapping peptide against systemic MRSA infections.Journal of advanced research · 2025Article
- Inhalable SPRAY nanoparticles by modular peptide assemblies reverse alveolar inflammation in lethal Gram-negative bacteria infection.Science advances · 2024Article
- Recent advances in graphene-based electroanalytical devices for healthcare applications.Nanoscale · 2024Review
- Amelioration of Subglottic Stenosis by Antimicrobial Peptide Eluting Endotracheal Tubes.Cellular and molecular bioengineering · 2023Article
- An optimized antimicrobial peptide analog acts as an antibiotic adjuvant to reverse methicillin-resistant Staphylococcus aureus.NPJ science of food · 2022Article
- Synergistic activity of pomegranate rind extract and Zn (II) against Candida albicans under planktonic and biofilm conditions, and a mechanistic insight based upon intracellular ROS induction.Scientific reports · 2022Article
- Heparin-Peptide Nanogranules for Thrombosis-Actuated Anticoagulation.Small (Weinheim an der Bergstrasse, Germany) · 2022Article
- Main-chain flexibility and hydrophobicity of ionenes strongly impact their antimicrobial activity: an extended study on drug resistance strains andRSC advances · 2022Article
- Bacterial Small Membrane Proteins: the Swiss Army Knife of Regulators at the Lipid Bilayer.Journal of bacteriology · 2022Review
- Disclosure of a Promising Lead to Tackle Complicated Skin and Skin Structure Infections: Antimicrobial and Antibiofilm Actions of Peptide PP4-3.1.Pharmaceutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 2 institutions in 1 country.
Funding
Abstract
Precision antimicrobials aim to kill pathogens without damaging commensal bacteria in the host, and thereby cure disease without antibiotic-associated dysbiosis. Here we report the de novo design of a synthetic host defence peptide that targets a specific pathogen by mimicking key molecular features of the pathogen's channel-forming membrane proteins. By exploiting physical and structural vulnerabilities within the pathogen's cellular envelope, we designed a peptide sequence that undergoes instructed tryptophan-zippered assembly within the mycolic acid-rich outer membrane of Mycobacterium tuberculosis to specifically kill the pathogen without collateral toxicity towards lung commensal bacteria or host tissue. These mycomembrane-templated assemblies elicit rapid mycobactericidal activity and enhance the potency of antibiotics by improving their otherwise poor diffusion across the rigid M. tuberculosis envelope with respect to agents that exploit transmembrane protein channels for antimycobacterial activity. This biomimetic strategy may aid the design of other narrow-spectrum antimicrobial peptides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.